Anti-Idiotypes Against Autoantibodies to Procoagulant Factor VIII (VIII:C) in Intravenous Immunoglobulins

References

• Inihach P., Barandun S., d'Apuzzo V. High dose intravenous gammaglobulin, for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228–1230
   PubMedGoogle Scholar
• Newland A. C., Treleaven J. G., Minchmton R. M., Waters A. M. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 11: 84–87
   Google Scholar
• Schmidt R. E., Budde U., Schafer G. High-dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura. Lancet 1981; 11: 475–476
   Google Scholar
• Bussel J. B., Kimberly R. P., Inman R. D. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62: 480–486
   PubMed Web of Science ®Google Scholar
• Pollack S., Cunningham-Rundles C., Smithwick E. M., Barandun S., Good R. A. High-dose intravenous gammaglobulin for autoimmune neutropenia. N. Engl. J. Med. 1982; 307: 243–255
   PubMedGoogle Scholar
• Bussel J. B., Lalezari P., Hilgartner M. W. Reversal of neutropenia with intravenous gamma globulin in autoimmune neutropenia of infancy. Blood 1983; 62: 398–400
   PubMed Web of Science ®Google Scholar
• Hilgartner M. W., Bussel J. B. Use of intravenous gammaglobulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am. J. Med. 1987; 83(suppl 4A)25–29
   PubMedGoogle Scholar
• Bussel J. B., Cunningham-Rundles C., Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high doses of gamma globuli. Vox Sang 1987; 51: 264–269
   Google Scholar
• McIntyre E. A., Linch D. C., Macey M. G., Newland A. C. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemi. Br. J. Haematol. 1985; 60: 287–288
   Google Scholar
• Clauvel J. P., Vainchenker W., Herrera A. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br. J. Haematol. 1983; 55: 380–382
   PubMedGoogle Scholar
• McGuire W. A, Yong H. H., Bruno E., Brandt J., Bridell R., Coates T. D., Hoffman R. Treatment of antibody-mediated pure red cell aplasia with high dose intravenous gammaglobulin. N. Eng. J. Med. 1987; 317: 1004–1008
   PubMedGoogle Scholar
• Gajdos P. H., Outin H., Elkarrat D. High-dose intravenous immunoglobulin for myasthenia gravis. Lancet 1984; 1: 406–407
   PubMed Web of Science ®Google Scholar
• Vermeulen M., van der Meche F. G. A., Speelman J. D., Weber A., Busch H. F. M. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J. Neurol. Sci. 1985; 70: 317–326
   PubMed Web of Science ®Google Scholar
• Albala M., McNanara M. E., Sokol M., Wijshock E. Improvement of neurologic function in chronic inflammatory demyelinating polyradiculoneuropathy following intravenous gammaglobulin infusion. Arch. Neurol. 1987; 44: 248–249
   PubMedGoogle Scholar
• Sultan Y., Kazatchkine M. D., Maisonneuve P., Nydegger U. E. Anti-idiotypic suppression of autoantibodies to Factor VIII by high-dose intravenous gammaglobulin. Lancet 1984; 11: 765–768
   Google Scholar
• Zimmerman R., Kommerell B., Harenberg J., Eich W., Rother K., Schimps K. L. Intravenous IgG for patients with spontaneous inhibitor to Factor VII. Lancet 1985; 1: 273–274
   Google Scholar
• Green D., Kwaan H. C. An acquired Factor VIII inhibitor responsive to high-dose gammaglobulin. Thromb Haemost. 1987; 58: 1005–1007
   PubMed Web of Science ®Google Scholar
• Morell A., Nydegger U. E. Clinical use of intravenous immunoglobulins. Academic Press, London 1986
   Google Scholar
• Gordon D. S. Intravenous immunoglobulin therapy. New directions and unanswered questions. Am. J. Med 1987; 83(suppl 4A)52–56
   PubMedGoogle Scholar
• Fehr J., Hofmann Kappeler V. U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N. Engl. J. Med. 1982; 306: 1254–1258
   PubMed Web of Science ®Google Scholar
• Kimberly R. P., Salmon J. E., Bussel J B., Crow M. K., Hilgartner M. W. Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J. Immunol. 1984; 132: 745–750
   PubMed Web of Science ®Google Scholar
• Bussel J., Pahwa S., Porges P. Changes in the in vitro antibody synthesis in ITP treated with intravenous gammaglobulin are closely kinked to long-term outcome. J. Clin. Immunol. 1986; 6: 50–56
   PubMedGoogle Scholar
• Delfraissy J. F., Tchernia J., Laurian Y. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 1985; 60: 315–322
   PubMed Web of Science ®Google Scholar
• Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous us. J. Immunol. 1986; 136: 4407–4413
   PubMedGoogle Scholar
• Tsubakio T., Kurata Y., Katagiri S. Alteration of T cell subsets and immunoglohulin synthesis in vitro during high-dose gammaglobulin therapy in patients with idiopathic thrombocytopenic purpura. Clin. Exp. Immunol. 1983; 53: 697–702
   PubMed Web of Science ®Google Scholar
• Uhr J. W., Moller G. Regulatory effect of antibody on the immune response. Adv. Immunol 1968; 8: 81–84
   PubMedGoogle Scholar
• Rossi F., Sultan Y., Kazatchkine M. D. Spontaneous and therapeutic suppression of autoimmune response to Factor VIII by anti-idiotypic antibodies. Clinical Use of Intravenous Immunoglobulins, U. E. Nydegger, A. Morell. Academic Press, London 1968; 421
   Google Scholar
• Sultan Y., Rossi F., Kazatchkine M. D. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-VIII:C autoantibodies. Proc. Natl. Acad. Sci., U.S.A. 1987; 84: 828
   PubMed Web of Science ®Google Scholar
• Rossi F., Sultan Y., Kazatchkine M. D. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-hemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin. Exp. Immunol. 1988; 74: 311–316
   PubMed Web of Science ®Google Scholar
• Rossi F., Dietrich G., Kazatchkine M. D. Anti-idiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. Res. Immunol. 1989; 140: 19–31
   PubMedGoogle Scholar
• Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to F-VIII. Thrombos. Haemostas. 1981; 45: 200–203
   PubMed Web of Science ®Google Scholar
• Shapiro S. S., Hultin M. Acquired inhibitors to the blood coagulation factors. Sem. Thromb. Hem. 1975; 1: 336–385
   Google Scholar
• Foster P. A., Fulcher C. A., Houghten R. A., de Gaaf Mahoney S., Zimmerman T. S. Localization of the binding regions of a murine monoclonal anti-Factor VIII:C antibody and a human anti-Factor VIII alloantibody, both of which inhibit Factor VIII procoagulant activity to amino acid residues threonine251-serine365 of the Factor VIII heavy chain. J. Clin. Invest. 1988; 82: 123–128
   PubMedGoogle Scholar
• Allain J. P, Gaillondre A., Lee H. Immunochemical characterization of antibodies of Factor VIII in hemophilic and non hemophilic patients. J. Lab. Clin. Med. 1981; 97: 807–813
   Google Scholar
• De la Fuente B., Hoyer L. W. The idiotypic characteristics of human antibodies to Factor VIII. Blood 1984; 64: 672–678
   PubMedGoogle Scholar
• Kasper C. K., Aledort L. M., Counts R. B. A more uniform measurement of F VIII inhibitors. Throm. Diath Haemorrh. 1975; 34: 869–872
   PubMedGoogle Scholar
• Couraud P. D., Lu B. Z., Strosberg A. D. Cyclical anti-idiotypic response to anti-hormone antibodies due to neutralization by autologous anti-idiotypic antibodies that bind hormone. J. Exp. Med. 1983; 157: 1369–1373
   PubMed Web of Science ®Google Scholar
• Abdou M. I., Wall H., Lindsey H. B., Hasley J. F., Susuki T. Network theory in autoimmunily: in vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J. Clin. Invest. 1981; 67: 1297–1304
   PubMed Web of Science ®Google Scholar
• Pasquali J. L., Urlacher A., Storck D. Idiotypic network: possible explanation of seronegativity in a patient with rheumatoid arthritis. Clin. Exp. Immunol. 1984; 55: 281–286
   PubMedGoogle Scholar
• Roitt I. M., Cooke A. Idiotypes and autoimmunity. Progress in Immunology, B. Cinader, R. G. Miller. Academic Press, New York 1986; 512
   Google Scholar
• Ruiz-Arguelles A. Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an anti-idiotpyic antibody directed to an interspecies cross-reactive idiotype expressed on anti-fibrinogen antibodies. J. Clin. Invest. 1988; 82: 958–963
   PubMedGoogle Scholar
• Rossi F., Kazatchkine M. D. Anti-idiotypes against autoantibodies in pooled normal immunoglobulins for therapeutic use. J. Immunol. 1989, in press.
   Google Scholar
• Tankersley D. L., Preston M. S., Finlayson J. S. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol. Immunol. 1988; 25: 41–48
   PubMedGoogle Scholar
• Jerne N. K. Towards a network theory of the immune response. Ann Immunol. (Inst. Pasteur, Paris) 1984; 125: 373–389
   Google Scholar